hepatitis b virus core

The hepatitis B virus (HBV) core protein has been found in the nucleus, the cytoplasm, or both of HBV-infected hepatocytes. nuclear localization of the HBV core protein is negatively regulated by phosphorylation during the cell cycle.

Linvencorvir (RG7907) belongs to HBV core protein allosteric modulators (CpAM) and is an orally active HBV core protein inhibitor with potent anti-HBV activity, low CYP3A4 induction, and good metabolic stability. This compound is used for the treatment of chronic hepatitis B virus infection.

Canocapavir (ZM-H1505R) is a novel orally available HBV coat protein modulator with antiviral activity that induces conformational changes in the linker region of the HBV core protein, and can be used for the treatment of hepatitis B virus.

KR019 is a potent hepatitis B virus (HBV) capsid assembly modulator that demonstrates significant antiviral activity in HBV cells. It binds to the hydrophobic pocket at the core protein dimer-dimer interface, redirecting capsid assembly into genome-free capsids, thereby inhibiting viral replication.

CAB7-3 is an orally effective HBV capsid assembly modulator that demonstrates excellent antiviral potency. It inhibits HBVDNA with an EC50 of 70 nM and has a CC50 of 32.3 μM. The compound exhibits significant anti-HBV activity across various cell models, with EC50 values of 70 μM in HBV-integrated HepDES19 cells, 1 nM in tetracycline-induced HepAD38 cells, and 2 nM in HBV-infected HLCZ01 cells. In vivo, CAB7-3 effectively reduces hepatic HBV core protein levels and suppresses viral replication. It shows good drug-like properties and safety, making it suitable for hepatitis B virus research.

AT-130 is a HBV virus inhibitor with improved potency (IC50 = 0.13 μM) and reduced toxicity in the HepAD38 cell line. AT-130 blocks HBV replication at the level of viral RNA packaging.

AB-836, an orally active hepatitis B virus (HBV) capsid inhibitor, hampers viral replication by engaging with the HBV core protein.

AB-506 is a compound that serves as an orally administered inhibitor specifically targeting the hepatitis B virus (HBV) core protein to obstruct HBV replication. It achieves this by binding to the HBV core protein, accelerating capsid assembly, and hindering the encapsidation of HBV pre-genomic RNA (pgRNA). Consequently, AB-506 is utilized in the study of chronic hepatitis B (CHB).

HBV Seq1 aa:93-100 is a peptide fragment of the hepatitis B virus (HBV) core antigen spanning amino acids 93 to 100 [1].

HBV Seq1 aa:18-27 is a hepatitis B virus (HBV) core antigen peptide fragment spanning amino acids 18-27 [1].

Vebicorvir (ABI-H0731), a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity.

HBcAg (core antigen) is a hepatitis B viral protein. It is an indicator of active viral replication; this means the person infected with Hepatitis B can likely transmit the virus on to another person.